When chimeric antigen receptor (CAR) T-cell therapies were first approved for cancer in 2017, nurses didn’t have years of clinical practice experience with the treatment to understand its full scope of nursing implications yet. Now that nearly five years have passed—and new CAR T-cell therapies have been approved, bringing the total number of treatments to five as well—oncology nurses and nurse scientists have built a robust knowledge base.
As individual diseases, cancer diagnoses like pheochromocytoma (cancer of the adrenal gland), neuroendocrine cancers, and malignant mixed Mullerian tumors (also called carcinosarcomas) are rare, but collectively they’re more common than breast, colon, lung, or prostate cancer.
On March 10, 2021, the U.S. Food and Drug Administration approved tivozanib (Fotivda®), an oral kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
Nurses don’t always have to venture beyond the bedside for unique career change opportunities. Always innovating and evolving, the profession identifies new roles for clinical practice nurses to meet patients’ needs.
As a nurse, you have a diverse arsenal of skills, from clinical competencies and leadership to problem-solving and interprofessional communication. That skillset easily transfers to a variety of careers outside of direct care.
- Patient-Advocacy-Provider Partnerships and Networks Support Rare Cancer Research
- Membership Dues Remain Level at $125 for 2022
- ONS Joins Oncology Organizations to Improve Patient Understanding and Outcomes for IV Cancer Therapies
- Prognostic Biomarkers May Help Predict Rhabdomyosarcoma Outcomes